ポスト
In a randomized trial of perioperative nivolumab as compared with chemotherapy, 18-month event-free survival was 70% in the nivolumab group and 50% in the chemotherapy group at 2-year median follow-up. Read the full CheckMate 77T phase 3 trial results: https://t.co/9cFFoyU0JH
メニューを開く
